Discovering next-generation combination therapies and immunotherapies for lung cancer patients
Bidragets beskrivning
Lung cancer is the biggest cancer killer in men and the second biggest in women in Finland (Syöpärekisteri, 2018). 10-15% of the adenocarcinomas in non-smoker patients harbor mutations in epidermal growth factor (EGFR) gene. EGFR inhibitors have improved the life expectancy of these patients, but typically drug resistance forms within 9-14 months. Every cell in the tumor is different (=tumor heterogeneity), and only some cells have the capacity to form resistance. Dr. Haikala's research performed in the University of Helsinki is studying how tumor heterogeneity contributes to formation of drug-resistant miroenvironment and therapy resistance. The study aims to find better targeted and immunotherapy combinations for lung cancer patients to achieve long lasting treatment effects. The research utilizes cutting edge research models including microfluidic and organoid 3D cultures from fresh tumor tissue collected from consented patients in collaboration with the University Hospital.
Visa merStartår
2021
Slutår
2024
Beviljade finansiering
Finansiär
Finlands Akademi
Typ av finansiering
Forskardoktorer
Utlysning
Övriga uppgifter
Finansieringsbeslutets nummer
339167
Vetenskapsområden
Biomedicinska vetenskaper
Forskningsområden
Biolääketieteet
Identifierade teman
cancer